



## Improving Patient Outcomes in Fibromyalgia Syndrome: A Clinical Update on Appropriate Diagnosis, Adequate Treatment, and Proper Management of Comorbid Conditions

Participate in the CME-certified multimedia activity featured in this podcast. Go online now at:

[www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

### Program Faculty

#### Course Director

**Daniel J. Clauw, MD**  
University of Michigan Medical School  
Ann Arbor, Michigan

**Philip J. Mease, MD**  
University of Washington School of Medicine  
Swedish Hospital Medical Center  
Seattle, Washington

**Andrew F. Leuchter, MD**  
David Geffen School of Medicine at UCLA  
Semel Institute for Neuroscience  
and Human Behavior at UCLA  
Los Angeles, California

#### CME Reviewers

**Edwin Jacobson, MD**  
David Geffen School of Medicine at UCLA  
Los Angeles, California

**Ian A. Cook, MD**  
Semel Institute for Neuroscience  
and Human Behavior at UCLA  
Los Angeles, California

#### Content Director

**Kirk A. Tacka, PhD**  
PVI, PeerView Institute for Medical Education, Inc.



This CME activity is sponsored by the Semel Institute for Neuroscience and Human Behavior at UCLA and the Institute for Medical Education, in association with PVI, PeerView Institute for Medical Education.



This activity is supported by an educational grant from Forest Laboratories Inc.

To complete the post-test and evaluation for CME credit please click here: [www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

Participate in the CME-certified multimedia activity featured in this podcast.  
Go online now at:

[www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

#### General Information

##### Requirements for Successful Completion:

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

<b>Media:</b>	Internet
<b>Release Date:</b>	October 26, 2009
<b>Expiration Date:</b>	October 25, 2010
<b>Estimated time to complete activity:</b>	45 minutes
<b>Sponsorship:</b>	This CME activity is sponsored by the Semel Institute for Neuroscience and Human Behavior at UCLA and the Institute for Medical Education, in association with PVI, PeerView Institute for Medical Education.
<b>Support:</b>	This activity is supported by an educational grant from Forest Laboratories Inc.

#### Faculty Disclosures/Conflict of Interest Policy

In accordance with ACCME requirements, the Semel Institute for Neuroscience and Human Behavior at UCLA and the Institute for Medical Education, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

**Daniel J. Clauw, MD**, has a financial interest/relationship or affiliation in the form of: Consultant for AstraZeneca, Ltd.; Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Pfizer Inc; and Pierre Fabre Pharmaceuticals Inc.

**Philip J. Mease, MD**, has a financial interest/relationship or affiliation in the form of: Consultant for Allergan, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Fralex Therapeutics Inc.; Jazz Pharmaceuticals, Inc.; Pfizer Inc; and Wyeth Pharmaceuticals Inc.  
Grant/Research Support from Allergan, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Fralex Therapeutics Inc.; Jazz Pharmaceuticals, Inc.; Pfizer Inc; and Wyeth Pharmaceuticals Inc.  
Speakers Bureau participant with Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Pfizer Inc; and Wyeth Pharmaceuticals Inc.

**Andrew F. Leuchter, MD**, has a financial interest/relationship or affiliation in the form of: Consultant for Aspect Medical Systems; AstraZeneca, Ltd.; Eli Lilly and Company; GlaxoSmithKline; MEDACorp; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc; and Takeda Pharmaceuticals North America, Inc.  
Grant/Research Support from Aspect Medical Systems; Eli Lilly and Company; MedAvante, Inc.; Merck & Co., Inc.; National Center for Complementary and Alternative Medicine; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Pfizer Inc; VivoMetrics; and Wyeth Pharmaceuticals Inc.  
Speakers Bureau participant with Eli Lilly and Company and Wyeth Pharmaceuticals Inc.  
Shareholder in Aspect Medical Systems.  
Advisory Board for Aspect Medical Systems; AstraZeneca, Ltd.; Eli Lilly and Company; GlaxoSmithKline; MEDACorp; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc; and Takeda Pharmaceuticals North America, Inc.

To complete the post-test and evaluation for CME credit  
please click here: [www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

Participate in the CME-certified multimedia activity featured in this podcast.  
Go online now at:

[www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

**CME Reviewers:**

**Edwin Jacobson, MD**, currently has no financial interests/relationships or affiliations in relation to this activity.

**Ian A. Cook, MD**, has a financial interest/relationship or affiliation in the form of:

*Consultant* for Neuronetics, Inc. and Scale Venture Partners.

*Grant/Research Support* from Aspect Medical Systems; Neuronetics, Inc.; and Sepracor Inc.

*Speakers Bureau* participant with Wyeth Pharmaceuticals Inc.

**Content Director:**

**Kirk A. Tacka, PhD**, currently has no financial interests/relationships or affiliations in relation to this activity.

**Disclosure of Unlabeled Use**

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

**Target Audience**

This activity has been designed to meet the educational needs of psychiatrists and other clinicians who provide care for patients with fibromyalgia.

**Program Description**

This 3-part activity focuses on several aspects of the management of fibromyalgia. Highlights from the first part of the activity include the potential etiologies of fibromyalgia and tools to assist in the diagnosis of patients with this condition. The various types of pharmacologic and nonpharmacologic therapeutic approaches for fibromyalgia are discussed in the second part of the program. The third part of the activity addresses the treatment of comorbidity in patients with fibromyalgia. It also emphasizes the importance of an interdisciplinary approach for the management of fibromyalgia.

**Educational Objectives**

**Upon completion of this activity, participants should be better able to:**

- Discuss the potential underlying etiologies of fibromyalgia syndrome and assess the current methods used to diagnose this condition
- Analyze and interpret the recent clinical data related to pharmacologic and nonpharmacologic therapies for the treatment of fibromyalgia syndrome
- Propose strategies to manage comorbid conditions in patients with fibromyalgia syndrome

To complete the post-test and evaluation for CME credit  
please click here: [www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

Participate in the CME-certified multimedia activity featured in this podcast.  
Go online now at:

[www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

#### Accreditation and Credit Designation Statements

This program was developed and reviewed by faculty members of the David Geffen School of Medicine at UCLA. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Institute for Medical Education and the Semel Institute for Neuroscience and Human Behavior at UCLA, in association with PVI, PeerView Institute for Medical Education. The Institute for Medical Education takes responsibility for the content, quality and scientific integrity of this CME activity.

The Institute for Medical Education designates this educational activity for a maximum of 0.75 hour of *AMA PRA Category 1 Credit™*. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

#### Hardware/Software Requirements

PeerView Press requires minimum browser versions of: 6.x from Microsoft and Netscape; 2.x from Mozilla Firefox; or 3.x from Safari. Certain activities may require additional software to view. That software may be: Adobe Reader®, and Adobe® Flash® Player.

#### Privacy Policy

PeerView Press shares your concerns about maintaining the privacy of personal information collected on the Internet. PeerView Press ensures that confidentiality of data relating to individual visitors to a medical/health web site, including their identity, is respected by this web site. The web site owners undertake to honor or exceed the legal requirements of medical/health information privacy that apply in the country and state where the web site and mirror sites are located.

#### Privacy Policy Changes:

Minor changes to our privacy policy may occur. If privacy policies change in a way that significantly affects the way we handle personal information, we will not use the information we have previously collected without obtaining consent. We will post all privacy policy changes on our web site in a timely manner.

#### Collection of Personal Information from Site Users:

Visitors to PeerView Press can access and browse the site, without disclosing any personally identifiable information. PeerView Press does track some information provided by your browser, such as the time and date of access, the web site you came from, the type of browser used, and other information that does not personally identify you. Visitors registering for services such as email updates, or completing program evaluation forms are requested to provide personal information, such as name, contact information, and medical specialty. We clearly label which information is required for registration, and which information is optional, on our registration forms. PeerView Press will not collect personally identifiable information without consent and will not share this data with any external partners.

[Click here to see the full PeerView Press Privacy Policy](#)

To complete the post-test and evaluation for CME credit  
please click here: [www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

Participate in the CME-certified multimedia activity featured in this podcast.  
Go online now at:

[www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)

**Disclaimer**

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

To complete the post-test and evaluation for CME credit  
please click here: [www.peerviewpress.com/g2/r72](http://www.peerviewpress.com/g2/r72)